Eyetech Pharmaceuticals


Eyetech Pharmaceuticals
New York, NY
Founded: 2000

Why It's Fierce: Eyetech is the exception that proves the rule academics cannot run a company. New York University medical school professor David Guyer and Harvard medical school associate professor Anthony Adamis signed a $745 million collaboration with Pfizer in December to develop Macugen, an anti-vascular endothelial growth factor for age-related macular degeneration and diabetic macular edema. What will Eyetech do for an encore?

What to look for in 2003: The company expects to file a new drug application for Macugen in the coming months.

Eyetech Pharmaceuticals

Suggested Articles

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.

While screening Caenorhabditis elegans for genetic clues to the PI3K/Akt signaling pathway, scientists found a key protein for insulin synthesis.